Table 1.
Antibacterial activities presented as drug MICs at which no visible growth was observed
| Compound | Mol wt | Drug MICs (μg/ml or μM) for various strainsa: |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
S. aureus |
S. epidermidis |
MRSA |
S. pyogenes |
E. coli |
E. cloacae |
S. marcescens |
P. aeruginosa |
||||||||||
| μg/ml | μM | μg/ml | μM | μg/ml | μM | μg/ml | μM | μg/ml | μM | μg/ml | μM | μg/ml | μM | μg/ml | μM | ||
| Neomycinb | 908.88 | 0.57 | 0.63 | 0.1 | 0.1 | 145 | 159.5 | >1,160 | >1,280 | 5 | 5.5 | 2 | 2.2 | 2 | 2.2 | 582 | 640.4 |
| DPA 51 | 1,810.4 | 4.5–9.1 | 2.5–5 | 1.25 | 0.69 | >80 | >44.2 | 20–40 | 11–22† | 10–20 | 5.5–11† | 20 | 11.04 | 20–40 | 11–22† | 20–40 | 11–22† |
| DPA 52 | 1,802.42 | 2.5 | 1.4 | 1.25 | 0.69 | >80 | >44.4 | 40–80 | 22–44 | 20 | 11 | 20 | 11.1 | 20–40 | 11–22* | 40–80 | 22–44 |
| DPA 53 | 1,843 | 36.9 | 20* | 9 | 5 | >80 | >43.4 | >80 | >43.4 | 40 | 21.7 | 80 | 43.4 | 80 | 43.4 | 40 | 21.7 |
| DPA 54 | 1,823.01 | 5–10 | 2.7–5.5 | 2.5 | 1.4 | >80 | >43.9 | >80 | >43.9 | 80 | 43.9 | 80 | 43.9* | 20–40 | 11–22† | >80 | >43.9 |
| DPA 55 | 1,877.1 | 5 | 2.5 | 1.25 | 0.66 | >80 | >42.6 | 40–80 | 21–42 | 40 | 21.3 | 80 | 42.6* | 20–40 | 11–22† | >80 | >42.6 |
| DPA 56 | 1,851.06 | 2.3–4.6 | 1.25–2.5 | 1.1 | 0.63 | 80 | 43.2 | >80 | >43.2 | 20 | 10.3† | 19–37 | 10–20† | 37 | 20 | >80 | >43.2 |
| DPA 58 | 1,939.57 | 2.4 | 1.25 | 1.2 | 0.63 | >80 | >41.2 | >80 | >41.2 | 80 | 41.2 | 20 | 9.8 | 40 | 20.1 | >80 | >41.2 |
| DPA 60 | 1,995.27 | 5–10 | 2.5–5 | 1.2 | 0.63 | 40 | 20.1 | >80 | >40.1 | 20–40 | 10–20† | >80 | >40.1 | >80 | >40.1 | >80 | >40.1 |
| DPA 65 | 1,843 | 2 | 1 | 1.2 | 0.63 | 37 | 20.1 | >80 | >43.4 | 37 | 20 | >80 | >43.4 | >80 | >43.4 | 37 | 20 |
| DPA 71 | 1,706.91 | 10 | 6 | 1.25–2.5 | 0.7–1.5 | >80 | >46.9 | >80 | >46.9 | 40–80 | 23.5–47 | 20–40 | 12–24† | 20–40 | 12–24* | >80 | >46.9 |
| DPA 72 | 1,824.98 | >80 | >43.8 | 20 | 11 | >80 | >43.8 | >80 | >43.8 | >80 | >43.8 | >80 | >43.8 | 20–40 | 11–22† | >80 | >43.8 |
| DPA 73 | 1,823.09 | 2.3 | 1.25 | 1.1 | 0.63 | 80 | 43.9 | >80 | >43.9 | 9 | 5 | 10 | 4.9 | 9–18 | 5–10 | >80 | >43.9 |
| DPA 74 | 1,824.98 | 40 | 22 | 5 | 3 | >80 | >43.8 | >80 | >43.8 | >80 | >43.8 | 80 | 43.8 | >80 | >43.8 | >80 | >43.8 |
| DPA 75 | 1,833.04 | 2.5–5 | 1.4–2.7† | 1.25 | 0.68 | >80 | >43.6 | 40–80 | 22–44 | 20–40 | 11–22† | 40 | 21.8 | 20–40 | 11–22† | >80 | >43.6 |
| DPA 76 | 1,897.17 | 10–20 | 5.3–10.5 | 2.5–5 | 1.3–2.6 | >80 | >42.2 | >80 | >42.2 | 40 | 21.1 | 40 | 21.1 | 20–40 | 11–22† | >80 | >42.2 |
| DPA 77 | 1,917.2 | 19.2–38.3 | 10–20† | 2.3–4.8 | 1.25–2.5 | >80 | >41.7 | >80 | >41.7 | 40 | 20.8 | 38 | 19.8 | 40 | 20.9 | >80 | >41.7 |
| DPA 78 | 1,953.28 | 20 | 10† | 4.9 | 2.5 | 39 | 20 | >80 | >41.0 | 5–10 | 2.5–5 | 5 | 2.5 | 2.4–4.9 | 1.25–2.5 | >80 | >41.0 |
| DPA 79 | 2,017.41 | 10 | 5 | 2.5 | 1.25 | >80 | >39.7 | >80 | >39.7 | >80 | >39.7* | >80 | >39.7* | >80 | >39.7* | >80 | >39.7 |
| DPA 80 | 2,037.44 | 1.25–2.5 | 0.6–1.2 | 1.25 | 0.61 | 40 | 19.7 | 40–80 | 20–40 | 20 | 9.8 | 40 | 19.6* | >80 | >39.3* | >80 | >39.3 |
| DPA 81 | 2,934.88 | 1.25–2.5 | 0.4–0.9 | 2.5 | 0.85 | >80 | >27.3 | >80 | >27.3 | 20 | 6.8 | 80 | 27.3* | 20–40 | 7–14 | >80 | >27.3 |
a
Strains: S. aureus ATCC 25923, S. epidermidis ATCC 12228, methicillin-resistant S. aureus ATCC 33591, S. pyogenes ATCC 12384, E. coli ATCC 25922, E. cloacae ATCC 13047, S. marcescens ATCC 13880, and P. aeruginosa ATCC 27853. MICs for which the screening results were not clearly confirmed: *, ≥50% inhibition; and †, <50% inhibition in a single point screen.
b
That is, neomycin sulfate.